Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Smoking Cessation 1Ovarian Neoplasms 1Neoplasms, Second Primary 1Breast Neoplasms 1Behavior, Addictive 1

Interventions

pembrolizumab 522Specimen Handling 383Carboplatin 375Magnetic Resonance Spectroscopy 338Cisplatin 331Nivolumab 308Cyclophosphamide 299Radiotherapy 256Paclitaxel 256Gemcitabine 236Biopsy 235Bevacizumab 215Dexamethasone 170durvalumab 167Oxaliplatin 163Capecitabine 159Rituximab 156Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 141atezolizumab 140Doxorubicin 134Ipilimumab 130Prednisone 120Radiosurgery 119Lenalidomide 119Leucovorin 113fludarabine 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Bupropion × 1 year × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04634071 2026-02-02

TTOP

University of Kentucky

Phase 2 Completed
126 enrolled

Smoking Cessation, Neoplasms, Second Primary, Behavior, Addictive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡